RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-31. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== Peptides vs proteins and amino acids in the digestive tract == Any animal that consumes a whole protein must break down and digest the protein order to absorb the nutrients. For humans this begins with chewing and the addition of saliva enzymes, followed by acid and protease enzyme digestion in the stomach, whereby the end result is a peptide or amino acid fraction ready for uptake into the blood stream via the small intestine. Research has confirmed that most animals have more Peptide receptors in the gut and lower intestine than they do free amino acid receptors - as such the peptide form of fish protein powder is most conducive for optimal nutritional benefits. Hygienic production of fish protein powder mimics these natural digestion steps, and pending the degree of hydrolysis, the protein powder will actually be a partial or complete peptide powder, ready for immediate absorption in the intestine.
The Rejuvant study (a human clinical trial) reported that the median and range of the biological age of females before treatment was 62.15 (range, 46.4 to 73) years and fell to 55.55 (range 33.4 to 63.7) years after an average of 7 months treatment. These values for men were 61.85 (range 41.9 to 79.7) years before and 53.3 (33 to 74.9) years after treatment. Overall, the combined group of males and females showed an average fall in biological age of 8 years compared to before treatment. The p-value for this difference was extraordinarily significant, i.e., 6.538x10-12, in showing that this treatment decreased the participants' biological ages. However, the study did not: a) include a control group (i.e., concurrent study of individuals taking a placebo instead of Rejuvant®); b) determine if the retinyl palmitate, vitamin A, and/or calcium given with α-ketoglutarate contributed to the changes in biological ages; and c) disclose which genes were tracked for the methylation of their CpG island. The study recommended that studies need to include control groups taking a placebo or the appropriate dosages of retinyl palmitate, vitamin A, and calcium. Also, TruMe Labs, who were the maker and marketer of the biological age assay used in this study, sponsored part of the study and contributed three of its employees as authors to the study.
In rail transport, the Single European Railway Directive 2012 requires that ownership of tracks and operating companies are separated to prevent conflicts of interest and pricing, particularly to ensure that trains can run from one member state to another. Most European railways are publicly owned, and each train enterprise must have separate accounts and member states should run railways 'at the lowest possible cost for the quality of service required'. The Rail Passenger Rights Regulation 2007 article 17 states that 25% of a ticket price should be refunded if there is a one-hour delay, and 50% over two hours, with a threshold of €4 to claim. Passengers have a right to take bicycles on trains where they are not overcrowded, there must be clear information on tickets, and there are rights to make reservations. Finally, in air transport, under the Flight Compensation Regulation (EC) No 261/2004 there is a minimum right of €250 compensation for 2 hour delay on 1500 km flight, €400 compensation for 3 hour delay or more on a 1500–3500 km flight, and €600 for 4 hours in flights over 3500 km flight, plus the right to refreshments, hotels, and alternative transport. There are not yet duties on airline companies to invest in research for clean fuels, and eliminate unnecessary flight paths when clean land transport alternatives (such as high-speed rail) exist. Finally, the 'right to housing assistance' is a basic part of EU law. House prices are affected by monetary policy (above), but otherwise the EU's involvement is so far limited to minimal environmental standards.
== Techniques == Traditional gum grafting will have a piece of the gums harvested from the roof of the mouth and sutured facing the exposed root to increase the lost keratinized tissue. The limited amount of donor tissue available from the palate and morbidity are the limiting factors of this technique. Allografting can be used to supply the surgeon with larger amount of tissues when needed, but complications in healing and the risk of possible disease transmission should be considered and disclosed to the patient when opting for such technique.
Sources: en.wikipedia.org
A less common form of cement is non-hydraulic cement, such as slaked lime (calcium oxide mixed with water), which hardens by carbonation in contact with carbon dioxide, which is present in the air (~ 412 vol. ppm ≃ 0.04 vol. %). First calcium oxide (lime) is produced from calcium carbonate (limestone or chalk) by calcination at temperatures above 825 °C (1,517 °F) for about 10 hours at atmospheric pressure:
The use of MRI is currently contraindicated for patients with pacemakers, cochlear implants, some indwelling medication pumps, certain types of cerebral aneurysm clips, metal fragments in the eyes, some metallic hardware due to the powerful magnetic fields, and strong fluctuating radio signals to which the body is exposed. Areas of potential advancement include functional imaging, cardiovascular MRI, and MRI-guided therapy.
== Research == Roy's researches during his stint in the US was on protein folding and nuclear magnetic resonance studies of DNA and those researches identified the first hydropathy model which helped in predicting the exteriors and interiors of proteins by analyzing sequence information. He is also reported to have performed the complete assignment of a nucleic acid imino proton spectra using Nuclear Overhauser effect, regio-specific isotope labeling of sugars in nucleic acids and working along with Ad Bax and R. H. Griffey, developed an indirect 2D-NMR detection method, all reported to be for the first time. Later focusing his attention on bacteriophage lambda, he studied the gene expression of the bacterial virus using its operator-repressor system. Through his collaborative work with Sankar Adhya in 1998, he elucidated the role of differential contact in the transcription regulation mechanism and demonstrated the theory in many genetic regulatory circuits. His current work is focused on peptide therapeutics and he holds patents for some of his work. Roy has published his research work through a number of articles published in peer-reviewed journals and ResearchGate, an online repository of scientific papers, has listed 155 of them. He is the Co-author of "Chemical Biology of the Genome" published by Elsevier/AP. He is a joint editor of Subcellular Biochemistry, volume on Proteins: Structure, Function, and Engineering published by Plenum Press, New York, USA and Protein-Protein interaction Regulators published by Royal Society of Chemistry, UK.
Following the ban on Sufi orders in the Republic of Turkey, the Bektashi community's headquarters was moved from Hacıbektaş in central Anatolia, to Tirana, Albania. In Albania, the Bektashi community declared its separation from the Sunni community and they have since perceived as a distinct Islamic sect rather than a branch of Sunni Islam. Among the most famous followers of Bektashi in Balkans during the 19th century were Ali Pasha of Yanina and Naim Frashëri.
1956: The association "La Maternité Heureuse," which would become the French Movement for Family Planning (MFPF) in 1960, is founded; its goals include sex education and advocacy for the right to contraception and abortion. December 11, 1956: Law on the housewife allowance, extended beyond agricultural professions. March 25, 1957: Treaty of Rome establishing the European Economic Community; it includes a principle of equal pay for men and women for identical work.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.